Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- CheckyesterdayChange DetectedThe study page no longer displays the MedlinePlus Genetics-related Type 2 diabetes topic entry. The trial’s study details remain unaffected.SummaryDifference0.2%

- Check8 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a Phase 4 study of dapagliflozin added to metformin for people with type 2 diabetes, with details on its design, eligibility, outcomes, and location, replacing the error page.SummaryDifference50%

- Check15 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2; the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA notice about NIH websites transitioning from the term “Artificial Intelligence” to “Super Intelligence” appears above the study record page, which still displays a 403 error.SummaryDifference1%

- Check28 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.